« Recent News

Vermillion to Report Second Quarter 2016 Financial Results and Host Investor Conference Call on August 10th

AUSTIN, Texas, July 29, 2016 — Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its second quarter financial results on Wednesday, August 10, 2016, followed by an investor conference call and webcast at 8:00 a.m. (ET).

Conference Call and Webcast:

Wednesday, August 10th @ 8:00 a.m. (ET)

Domestic: 

888-523-1228

International: 

719-457-2689

Conference ID: 

4603836

Webcast: 

http://public.viavid.com/index.php?id=120291

Replay, available through August 25th:

Domestic: 

877-870-5176 

International: 

858-384-5517 

Replay PIN: 

4603836

 

About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women conquer serious diseases.  The company’s initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
[email protected]